NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. (“Spruce” or the “Company”) (NASDAQ: SPRB). Such investors are
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint
Positive Data from CAHptain-205 Study of.
Precedential Decisions - Penumbra, Inc. v. RapidPulse, Inc., IPR2021-01466, Paper 34 (March 10, 2023) (designated: November 15, 2023) (regarding prior art status under.
Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today.
Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief.